Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: Role of interleukin 17 and tumor necrosis factor-α

Journal of Rheumatology

Volumn 31, Issue 7, 2004, Pages 1246-1254

  Stamp, Lisa K ^a   Cleland, Leslie G ^a   James, Michael J ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Cyclooxygenase; Eicosanoids; Synoviocytes; T lymphocytes

Indexed keywords

ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; CYCLOOXYGENASE 2; CYCLOSPORIN A; INTERLEUKIN 17; NEUTRALIZING ANTIBODY; PROSTAGLANDIN E2; RECOMBINANT CYTOKINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; FIBROBLAST; HUMAN; HUMAN CELL; INFLAMMATION; LYMPHOCYTIC INFILTRATION; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CELL CULTURE TECHNIQUES; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-17; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SYNOVIAL MEMBRANE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 3042733572     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Firestein G, Alvaro-Garcia J, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990;144:3347-53.
2. Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994;91:8562-6.
3. Ulfgren AK, Lindbald S, Klareskog L, Andersson J, Andersson U. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:654-61.
4. Dolhain R, van den Heiden A, ter Haar N, Breedveld FC, Miltenburg A. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1961-9.
5. Barnes P, Fong S-J, Brennan P, Twomey P, Mazumder A, Modlin R. Local production of tumour necrosis factor and IFN-γ in tuberculous pleuritis. J Immunol 1990;145:149-54.
6. Dolhain R, ter Haar N, Hoefakker S, et al. Increased expression of interferon-gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Br J Rheumatol 1996;35:24-32.
7. Brennan FM, Maini RN, Feldmann M. TNFα - a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992;31:293-8.
8. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-15.
9. Ziolkowska M, Koc A, Luszczykiewics G, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000;164:2832-8.
10. Jovanovic D, Di Battista J, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines IL-1β and TNF-α by human macrophages. J Immunol 1998;160:3513-21.
11. Chabaud M, Fossiez F, Taupin J-L, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukaemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161:409-14.
12. Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumour necrosis factor-α-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts. Arthritis Rheum 2001;44:2176-84.
13. 2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum 2001;44:2078-83.
14. James M, Walsh J. Inter-relationships between vascular thrombosis and prostacyclin synthesis. Prostaglandins Leukot Essent Fatty Acids 1988;31:91-5.
15. Caldwell BV, Burstein S, Brock WA, Speroff L. Radioimmunoassay of the F prostaglandins. J Clin Endocrinol 1971;33:171-5.
16. Werner C, Klouda P, Correa M, Vassalli P, Jeannet M. Isolation of B and T lymphocytes by nylon fiber wool columns. Tissue Antigens 1977;9:227-9.
17. Neidhart M, Seemayer CA, Hummel K, Michel BA, Gay R, Gay S. Functional characterization of adherent synovial fluid cells in rheumatoid arthritis. Arthritis Rheum 2003;48:1873-80.
18. Demasi M, Caughey GE, James MJ, Cleland LG. Assay of cyclooxygenase-1 and 2 in human monocytes. Inflamm Res 2000;49:737-43.
19. 2 in nonadherent human monocytes. J Immunol 1997;158:351-8.
20. Pouliot M, Baillargeon J, Lee J, Cleland L, James M. Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-activated protein kinase. J Immunol 1997;158:4930-7.
21. Chabaud M, Miossec P. The combination of tumour necrosis factor-α blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001;44:1293-303.
22. Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: A novel cytokine derived from T cells. J Immunol 1995;155:5483-6.
23. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-603.
24. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999;162:1246-511.
25. 2 production in human monocytes: Implications for the use of cyclooxygenase inhibitors. J Immunol 2000;165:1605-11.
26. 2 dependent production of interleukin-11 in rheumatoid synovial fibroblasts. Arthritis Rheum 1998;41:2004-13.
27. Alaaeddine N, Di Battista J, Pelletier J, Kiansa K, Cloutier JM, Martel-Pelletier J. Inhibition of tumor necrosis factor α-induced prostaglandin E production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritis synovial fibroblasts. Arthritis Rheum 1999;42:710-8.
28. Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-α on macrophage inflammatory protein-3α production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001;167:6015-20.
29. Yamamura Y, Gupta R, Morita Y, et al. Effector function of resting T cells: Activation of synovial fibroblasts. J Immunol 2001;166:2270-5.
30. Dudler J, Renggli-Zulliger N, Busso N, Lotz M, So A. Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann Rheum Dis 2000;59:529-32.
31. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002;46:802-5.
32. Koshy PJ, Henderson N, Logan C, Life P, Cawston T, Rowan A. Interleukin 17 induces cartilage breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002;61:704-13.
33. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
34. Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-77.
35. Lubberts E, Joosten L, Oppers B, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001;167:1004-13.
36. Weinblatt ME, Kremer J, Bankhurst A, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
37. Moreland L, Schiff M, Baumgartner S, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
38. Maini RN, Breedveld FC, Kalden J, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor-α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
39. Bresnihan B, Alvaro-Garcia J, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
40. Jiang Y, Genant H, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1001-9.
41. Chevrel G, Garnero P, Miossec P. Addition of interleukin-1 (IL-1) and IL-17 soluble receptors to a tumour necrosis factor α soluble receptor more effectively reduces the production of IL-6 and macrophage inhibitory protein-3α and increases that of collagen in an in vitro model of rheumatoid synoviocyte activation. Ann Rheum Dis 2002;61:730-3.